Impact of pharmacotherapies for achondroplasia – Discussion 4 / 4

touchMDT for touchENDOCRINOLOGY

Listen to experts Prof. Karin Blakemore, Prof. Klaus Mohnike, Prof. Janet Legare and patient advocate Carly Kutner provide their insights on the impact of pharmacotherapies for achondroplasia

The multidisciplinary team and patient advocate:

MFM specialist - Prof. Karin Blakemore
Johns Hopkins University School of Medicine, Baltimore, MD, USA

Paediatric endocrinologist - Prof. Dr. med. Klaus Mohnike 
Otto-von-Guericke University Magdeburg, Magdeburg, Germany  

Paediatrician - Prof. Janet Legare
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Patient advocate - Ms Carly Kutner
Freehold, NJ, USA

This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from BioMarin Pharmaceutical Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchendocrinologyime.org/mdt-diagnosis-monitoring-early-treatment-in- achondroplasia/